Ironwood Pharmaceuticals stock
IRWDNASDAQIronwood Pharmaceuticals, Inc., HealthcareISIN US46333X1081
71Score 71 out of 100, Strong
Price and trend
66 / 100
Price history
+56% in one yearThe chart shows daily closes over 17 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 23% above it.
Since November 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 90).
The price is 10% below its 52-week high. Largest decline in 17 years: 97% (July 2018 to May 2025).
Chart figures for advanced users
- SMA 50$3.96
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$3.95
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)90
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$3.04
- The lowest closing price of the last twelve months.
- Resistance$5.39
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Ironwood Pharmaceuticals, Inc. belongs to the Drug Manufacturers (Specialty & Generic) industry (United States) and, with a market value of $802.92M, is number 68 of 78 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $296.15M (down 15.7% year on year) and earnings of $24.02M (up 2,629.2%).
- MEQIRI Score 71 out of 100 (Strong): rank 119 of 714 in Healthcare, median 53.
Show more
- The P/E is 5.4 (Drug Manufacturers (Specialty & Generic) median 19.3, own median of recent years 17).
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Modestly valuedP/E 5.4, Drug Manufacturers (Specialty & Generic) median 19.3, own median 17.Valuation 100
- High marginNet margin 37.4% over the last 12 months, Drug Manufacturers (Specialty & Generic) median 8.6%.Profitability 92
- High return on capitalReturn on invested capital 36% in fiscal 2025, Drug Manufacturers (Specialty & Generic) median 7%.Profitability 92
Weaknesses
- Earnings per share fallingDown 25.9% a year since 2020.Growth 42
- Volatile share priceVolatility 79% a year over the last 12 months.Stability 46
- Revenue shrinkingRevenue down 5.3% a year since 2020.Growth 42
Its standout strengths are valuation and momentum, while stability and growth hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 68 to 71.
Fundamentals are strong, with strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
What lowers it
- stable momentum
- price near its 52-week high
Valuation
Valuation signal
UndervaluedClosing price of 11 Nov 2026, used by the daily score.
A fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at more than four times the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 18.1% on the twelve months before. Revenue has grown strongly since 2006, at around 27% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 100%, operating 40%, net 8%. Last 12 months: net 37%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 24 Feb 2027in 104 days
- Last reported
- 5 Nov 2026EPS reported $0.36 (expected $0.32)above expectations
Analyst estimates
- Earnings per share
- $1.28+4.9%
- Revenue
- $493.6M+5.8%
- Earnings per share
- $1.38+5.1%
- Revenue
- $515.43M+4.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +4.1%2026 guidance raised: revenue of $460 million to $485 million and adjusted EBITDA above $310 million, with LINZESS demand growing at a mid-single-digit rate.
“Our revenue guidance has increased to between $460 million and $485 million, and we expect adjusted EBITDA of greater than $310 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 2 insiders sold, $658,523 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Ironwood Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 71
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Amphastar PharmaceuticalsAMPH $1.22B76
- VetoquinolVETO.PA $1.13B77
- Harrow HealthHROW $1.1B39
- PharmanutraPHN.MI $906.68M62
- Collegium PharmaceuticalCOLL $770.98M52
- EvotecEVT.DE $624.43M32
- Alpha TeknovaTKNO $541M43
- EvolusEOLS $491.12M45
ETFs that hold Ironwood Pharmaceuticals
Held by 3 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.04% | 0.35% | €1.21B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.03% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.03% | 0.30% | €2.17B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 12 Nov 2026, previously Neutral
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.